 |
|
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(4):705-708. Published online 2024 May 20 DOI: https://doi.org/10.3350/cmh.2024.0372
|
|
Citations to this article as recorded by
 Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy
Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George
Hepatology International.2024;[Epub] CrossRef
|